Sarepta (SRPT) Soars 15% on Bullish Rating

Group 1 - Sarepta Therapeutics Inc. (NASDAQ:SRPT) experienced a significant share price increase of 15.25% to close at $18.67, driven by a bullish rating from Mizuho Securities [1][2] - Mizuho Securities upgraded Sarepta's rating from "neutral" to "outperform" and raised its price target by 36.8% from $19 to $26, indicating a 39% upside potential from the latest closing price [2] - The upgrade was influenced by strong sales of the Elevidys drug, which generated $131.5 million in the third quarter, surpassing the $50 million target, despite concerns over linked deaths [3] Group 2 - Sarepta reported a net loss of $180 million for the period from July to September, a reversal from a net income of $33.6 million in the same period last year [4] - Revenues decreased by 14.5% year-on-year, falling from $467 million to $399 million, attributed to lower sales from Elevidys due to a shipping suspension in June 2025 following death reports [4]